Abstract
Purpose
The purpose of this study was to test the reliability of the Swedish version of the Oxaliplatin-Associated Neurotoxicity Questionnaire (OANQ) administrated throughout a self-reported mobile phone-based system, a pilot study.
Methods
Twenty-three patients from two university hospitals and two regional hospitals who had been treated with oxaliplatin were included through purposive sampling between autumn 2013 to autumn 2014. A test-retest was performed through a mobile phone-based system, with a recall period of 1 h to determine the reliability of the questionnaire.
Results
Internal consistency was strong for the three domains of the scale (α > 0.840). The statistical analyses for the test-retest indicated that the OANQ was stable. Intraclass correlation (ICC) for symptom items and effect on daily activities items showed an overall excellent reproducibility at 69 and 83 %, respectively. The weighted kappa for symptom items and daily activities items showed an overall almost perfect agreement at 59 and 52 %, respectively. A paired samples t test did not reveal any significant differences between the two measures.
Conclusions
The OANQ was tested and considered a reliable assessment for capturing the oxaliplatin-induced peripheral neurotoxicity (OIPN) in patients receiving oxaliplatin. However, further reliability testing of the OANQ is needed.
Similar content being viewed by others
References
Grenon N, Chan J (2009) Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: a new guide for nurses. Clin J Oncol Nurs 13(3):285–296. doi:10.1188/09.CJON.285-296
Velasco R, Bruna J, Briani C et al (2014) Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Pschiatry 85(4):392–398. doi:10.1136/jnnp-2013-305334
André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. doi:10.1200/JCO.2008.20.6771
Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy’s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21(12):3307–3313. doi:10.1007/s00520-013-1905-5
Land SR, Kopec JA, Cecchini RS et al (2007) Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 25(16):2205–2211
Tofthagen C, McAllister RD, McMillan SC (2011) Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. Clin J Oncol Nurs 15(2):182–188. doi:10.1188/11.CJON.182-188
Park BS, Goldstein D, Krishnan AV et al (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. doi:10.3322/caac.21204
Kidwell K, Yothers G, Ganz P et al (2012) Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer. Cancer 118(22):5614–5622. doi:10.1002/cncr.27593
Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C (2006) Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56(1):13–16
Vatandoust A, Joshi R, Pittman KB et al (2014) A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer 22(2):513–518
Sereno M, Gutiérrez-Gutiérrez G, Gómez-Raposo C et al (2014) Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol 89(1):166–178. doi:10.1016/j.critrevonc.2013.08.009
Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515. doi:10.1016/j.ejca.2008.04.018
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. doi:10.1200/JCO.2013.54.0914
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367
Larsen ME, Rowntree J, Young AM et al (2008) Chemotherapy side-effect management using mobile phones. Conf Proc IEEE Eng Med Biol Soc 2008:5152–5155. doi:10.1109/IEMBS.2008.4650374
McCann L, Maguire R, Miller M, Kearney N (2009) Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS©) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care 18(2):156–164. doi:10.1111/j.1365-2354.2008.00938.x
Mirkovic J, Kaufman DR, Ruland CM (2014) Supporting cancer patients in illness management: usability evaluation of a mobile app. JMIR Mhealth Uhealth 2(3):e33. doi:10.2196/mhealth.3359
Maguire R, McCann L, Miller M, Kearney N (2008) Nurses’ perceptions and experiences of using of a mobile-phone-based advanced symptom management system (AsyMS©) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 12(4):380–386. doi:10.1016/j.ejon.2008.04.007
Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46(3):479–494. doi:10.1016/j.ejca.2009.12.008
Kopec JA, Land SR, Cecchini RS et al (2006) Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol 4(8):W1–W8
Leonard GD, Wright MA, Quinn MG et al (2005) Survey of oxaliplatin-associated neurotoxicity using and interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 16(5):16. doi:10.1186/1471-2407-5-116
Driessen CML, Kleine-Bolt KME, Vingerhoets AJJM, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881. doi:10.1007/s00520-011-1336-0
Cathomas R, Köberle D, Ruhstaller T et al (2010) Heated (37 °C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263–1270. doi:10.1007/s00520-009-0740-1
Drott JE, Starkhammar H, Börjesson S, Berterö C (2014) Oxaliplatin induced neurotoxicity among patients with colorectal cancer: documentation in medical records—a pilot study. Open J Nurs 4:265–274. doi:10.4236/ojn.2014.44031
Brislin RW (1970) Back-translation for cross-cultural research. J Cross-Cult Psychol 1(3):185–216. doi:10.1177/135910457000100301
Acquadro C, Conway K, Giroudet C, Mear I (2012) Linguistic validation manual for health outcome assessments. MAPI Institute, Lyon
Mokkink LB, Terweea CB, Patrick DL et al (2010) The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol 63(7):737–745. doi:10.1016/j.jclinepi.2010.02.006
Rosner B (2011) Fundamentals of biostatistics. Brooks, Boston
Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37(5):360–363
Polit DF (2014) Getting serious about test-retest reliability: a critique of retest research and some recommendations. Qual Life Res 23(6):1713–1720. doi:10.1007/s11136-014-0632-9
Field A (2013) Discovering statistics using IBM SPSS statistics: and sex and drugs and rock ‘n’ roll, 4th edn. Sage, Los Angeles
Polit DF, Beck CT (2012) Nursing research, generating and assessing evidence for nursing practice, 9th edn. Lippincott Williams & Wilkins, Philadelphia
Berger A, Edwards Neumark D, Chamberlain J (2007) Enhancing recruitment and retention in randomized controlled clinical trials of cancer symptom management. Oncol Nurs Forum 34(2):e17–e22
Ganz PA, Land SR, Antonio C et al (2009) Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv 3(3):137–147. doi:10.1007/s11764-009-0093-2
Paul C, Courtney R, Sanson-Fisher R et al (2014) A randomized controlled trial of the effectiveness of a pre-recruitment primer letter to increase participation in a study of colorectal screening and surveillance. BMC Med Res Methodol. 14:44 http://biomedcentral.com/1471-2288/14/44
Hobart JC, Cano SJ, Warner TT, Thompson AJ (2012) What sample sizes for reliability and validity studies in neurology? J Neurol 259(12):2681–2694. doi:10.1007/s00415-012-6570-y
Stull DE, Kline Leidy N, Parasuraman B, Chassany O (2009) Optimal recall periods for patient-reported outcomes: challenges and potential solutions. Curr Med Res Opin 25(4):929–942. doi:10.1185/03007990902774765
Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. doi:10.1016/j.pain.2014.09.020
Bakitas M (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331
Bennett BK, Park SB, Lin CSY, Friedlander ML, Kiernan MC, Goldstein D (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20(11):2959–2967
Beijers AJM, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. doi:10.1007/s00520-014-2242-z
Velikova G, Keding A, Harley C et al (2010) Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomized controlled trial. Eur J Cancer 46(13):2381–2388. doi:10.1016/j.ejca.2010.04.030
Dickinson R, Hall S, Sinclair JE, Bond C, Murchie P (2014) Using technology to deliver cancer follow-up: a systematic review. BMC Cancer 14:(1)311 http://biomedcentral.com/1471-2407/14/311
Børøsund E, Ruland CM, Moore S, Ekstedt M (2014) Nurses’ experiences of using an interactive tailored patient assessment tool one year past implementation. Int J Med Inform 83(7):e23–e34. doi:10.1016/j.ijmedinf.2013.10.010
Acknowledgments
The authors thank all patients for their participation in the study. We would also like to thank Gun Skire at CQ for the technical support and Karl Wallin at LARC and Kristofer Årestedt at IMH for the statistical support and discussions. We thank all nurses in the oncology clinics who had contributed to the recruitment of patients. We also are grateful to the Division of Nursing Science at the Department of Medical and Health Sciences for the financial support.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gustafsson, E., Litström, E., Berterö, C. et al. Reliability testing of oxaliplatin-associated neurotoxicity questionnaire (OANQ), a pilot study. Support Care Cancer 24, 747–754 (2016). https://doi.org/10.1007/s00520-015-2838-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-015-2838-y